Benjamin Haynor

Swayampakula Ramakanth

Ben Haynor

- On **October 28, 2025**, Ekso Bionics Holdings, Inc. entered into a securities purchase agreement for a **registered direct offering** of **769,490 shares** of common stock at **$4.81 per share**.  **[1549084_0001437749-25-032276_ekso20251029_8k.htm:1]** 
- The offering is anticipated to close around **October 30, 2025**, and is expected to generate approximately **$3.2 million** in net proceeds.  **[1549084_0001437749-25-032276_ekso20251029_8k.htm:1]** 
- The company plans to utilize the net proceeds for **general corporate purposes**, which may include research and development activities, selling, general and administrative costs, strategic initiatives, and working capital needs.  **[1549084_0001437749-25-032276_ekso20251029_8k.htm:1]** 
- Lake Street Capital Markets, LLC, acting as the placement agent, will receive a **cash fee of 6%** of the gross proceeds and a warrant to purchase **15,389 shares** of common stock at an exercise price of **$4.81 per share**.  **[1549084_0001437749-25-032276_ekso20251029_8k.htm:1]** **[1549084_0001437749-25-032276_ex_879235.htm:3]**

Ekso Bionics Announces $3.2 Million Registered Direct Offering

- **Ekso Bionics Holdings, Inc.** entered into a definitive agreement on **October 28, 2025**, to sell **769,490 shares** of common stock at a purchase price of **$4.81 per share** in a registered direct offering.  **[1549084_40936f5609f847ddb36e932ffda127f0_0]** 
- The offering is expected to generate **gross proceeds of $3.7 million** for the company.  **[1549084_40936f5609f847ddb36e932ffda127f0_0]** 
- The **closing of the offering** is anticipated around **October 30, 2025**.  **[1549084_40936f5609f847ddb36e932ffda127f0_0]** 
- The company intends to use the **net proceeds** for general corporate purposes, including research and development activities, strategic initiatives, and working capital needs.  **[1549084_40936f5609f847ddb36e932ffda127f0_0]**

Ekso Bionics Announces Registered Direct Offering

- **Ekso Bionics Holdings, Inc.** reported **Q3 2025 revenue of $4.2 million**, representing a **105% sequential rebound** from Q2 2025 and a **2% year-over-year increase**.  **[1549084_0001437749-25-031957_ex_849226.htm:0]** 
- The company's **gross margin increased to 60.3%** in Q3 2025, an improvement of **680 basis points year-over-year** and **2,050 basis points sequentially**.  **[1549084_0001437749-25-031957_ex_849226.htm:0]** 
- **Net loss improved by 31% year-over-year** and **48% sequentially** to **$1.4 million**, or **$0.54 per basic and diluted share**, for Q3 2025.  **[1549084_0001437749-25-031957_ex_849226.htm:0]** 
- As of September 30, 2025, Ekso Bionics held **$2.7 million in cash**.  **[1549084_0001437749-25-031957_ex_849226.htm:1]** 
- The company announced it is **exploring one or more strategic transactions**, which may involve acquiring a new line of business or selling all or substantially all of its current business.  **[1549084_0001437749-25-031957_ex_849226.htm:1]**

EKSO Bionics Reports Q3 2025 Financial Results and Explores Strategic Transactions

- Ekso Bionics reported **revenue of $4.2 million** for the third quarter of 2025, representing a **105% sequential increase** from Q2 2025 and a **2% year-over-year growth**.  **[1549084_7671f1c18f5f46c5880f48575ed805a8_0]** **[1549084_7671f1c18f5f46c5880f48575ed805a8_1]** 
- The company's **gross margin** for Q3 2025 increased to **60.3%**, an improvement of **2,050 basis points sequentially** and **680 basis points year-over-year**.  **[1549084_7671f1c18f5f46c5880f48575ed805a8_0]** **[1549084_7671f1c18f5f46c5880f48575ed805a8_1]** 
- **Net loss improved 48% sequentially** and **31% year-over-year** to **$1.4 million** for the third quarter of 2025.  **[1549084_7671f1c18f5f46c5880f48575ed805a8_0]** **[1549084_7671f1c18f5f46c5880f48575ed805a8_1]** 
- Ekso Bionics is **exploring one or more strategic transactions**, which could include acquiring a line of business in a different industry or selling all or substantially all of its current business.  **[1549084_7671f1c18f5f46c5880f48575ed805a8_2]** **[1549084_7671f1c18f5f46c5880f48575ed805a8_3]**

Ekso Bionics Reports Q3 2025 Financial Results and Strategic Review

- **CMS approved a lump sum reimbursement of $91,032 for Ekso Indego Personal**, effective April 1, 2024. The first claim was approved in Q2 2024, with significant pipeline growth reported in Q2 2025.  **[0001549084_2208963:6]** **[0001549084_2208963:11]** **[0001549084_2208963:12]** 
- The company is **scaling its Personal Health go-to-market strategy** through key distribution partnerships, including **National Seating & Mobility (Q1 2025)** and **Bionic P&O (Q2 2025)**, and launched **Ekso University in Q2 2025** to provide continuing education for neurological physical therapists.  **[0001549084_2208963:9]** **[0001549084_2208963:12]** 
- EKSO is **advancing AI innovation** by developing a foundation model for human motion, leveraging **~350,000 patient sessions and 15 million+ step-by-step data points**, and has been accepted into the **NVIDIA Connect Program**.  **[0001549084_2208963:13]** 
- The company maintains a strong global presence with **over 500 centers and 1,000 devices deployed worldwide** for neuro-rehabilitation, holding FDA clearance for multiple indications.  **[0001549084_2208963:6]** **[0001549084_2208963:8]**

EKSO Bionics Reports Q3 2025 Strategic Developments

- Ekso Bionics Holdings, Inc. (EKSO) entered into a **Secured Promissory Note and Security Agreement** with B. Riley Commercial Capital, LLC on **September 12, 2025**.  **[1549084_0001437749-25-029285_ex_862299.htm:0]** **[1549084_0001437749-25-029285_ekso20250917_8k.htm:1]** 
- This agreement provides a secured term loan of up to **$2.0 million** for working capital and general corporate purposes, bearing an interest rate of **10.0% per annum**.  **[1549084_0001437749-25-029285_ekso20250917_8k.htm:1]** **[1549084_0001437749-25-029285_ex_862299.htm:1]** 
- The loan includes an **exit fee of $200,000** (10% of the original principal) and matures on the earlier of receiving **$2.4 million** from a Qualified Financing or **September 14, 2026**.  **[1549084_0001437749-25-029285_ekso20250917_8k.htm:1]** **[1549084_0001437749-25-029285_ex_862299.htm:1]** 
- In connection with this new agreement, the company paid off and terminated a prior **$2.0 million** loan agreement with Banc of California on the same date.  **[1549084_0001437749-25-029285_ekso20250917_8k.htm:2]**

EKSO BIONICS HOLDINGS (EKSO)